Chikungunya virus vaccine - Moderna Therapeutics
Alternative Names: mRNA-1388; VAL-181388Latest Information Update: 28 Oct 2020
At a glance
- Originator Moderna Therapeutics
- Class RNA; RNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chikungunya virus infections
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for phase-I development in Chikungunya-virus-infections(Prevention) in USA (Parenteral, Injection)
- 11 Jul 2018 Moderna completes enrolment in its phase-I trial for Chikungunya virus infections (In volunteers, In adults, Prevention) in USA (Parenteral)
- 14 Sep 2017 Phase-I clinical trials in Chikungunya virus infections (Prevention) in USA (Parenteral)